Psoriasis is lifelong and is not curable. Although it is also marked by rapid cell growth, psoriasis is neither cancerous nor contagious.
In general, studies report the following features of its course:
The emotional and social consequences of psoriasis should not be underestimated.
Researchers have reported the following:
Some patients, particularly men, use alcohol and smoking as self-medication to reduce the emotional consequences of psoriasis. In fact, studies have found that people with psoriasis have higher mortality rates, mostly from heavy drinking. Smoking has also been cited as a major risk, particularly for pustular psoriasis. Some experts believe that drinking and smoking may actually cause biological damage that contributes to psoriasis itself.
However, smoking may delay the onset of psoriatic arthritis in some patients, depending on when they started the habit. Psoriatic arthritis tends to occur about a decade after psoriasis develops. One review of psoriasis patients showed that the condition appeared after about 13 years in nonsmokers, compared to 23 years in those who began smoking after the first onset of psoriasis. Psoriatic arthritis appeared after 8 years in people who smoked before developing psoriasis.
Folate Deficiency in Severe Psoriasis. Severe psoriasis can cause folate deficiency. Folate is a B vitamin that is important for nerve function, and prevents birth defects. It also prevents elevations of homocysteine, a factor that may play a critical role in heart disease.
Skin Cancers. Patients with severe psoriasis (who receive medications that affect the whole body) may be at higher-than-normal risk for developing cancers, primarily skin cancers and lymphomas. The risk is not any higher in patients with milder psoriasis. There is some indication, however, that patients with psoriasis have a higher risk for non-melanoma skin cancers, regardless of treatments.
Obesity, diabetes, and heart risks: There are also increased risks of diabetes, heart disease, heart attacks, and cancer in patients with psoriasis. It is not yet known whether there are genetic links between psoriasis and some of these conditions. The connection may also have to do with shared risk factors, such as smoking and obesity. Patients with moderate-to-severe psoriasis should be screened, and possibly treated, for cardiovascular risks.
Impaired Temperature Regulation. Erythrodermic psoriasis (in which psoriasis covers the entire skin) can cause abnormalities in the body's ability to regulate temperature.
Zumbusch Psoriasis. A combination of erythrodermic and pustular psoriasis causes a serious condition called Zumbusch psoriasis:
Zumbusch psoriasis can be life threatening, particularly in the elderly. The condition is very rare in children and, if it occurs, tends to improve more quickly than in adults, possibly even without medication.
Most cases of psoriatic arthritis (PsA) are mild, but complications can occur:
Some earlier studies indicated that patients with psoriatic arthritis had a shorter lifespan than the general population, but more recent studies found no significant difference.
Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT, Chen CM. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Derm. 2008;144:1571-1575.
Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006 Oct 11;296(14):1735-41.
Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004. J Am Acad Dermatol. 2008 [Epub ahead of print].
Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-1674.
Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 2008;4(3):e1000041.
Menter A, Gottlieb A, Feldman SR, Voorhees ASV, Leonardi CL, Gordon KB, et al. Guidelines for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2008;5:826-850.
Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272-284.
Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241-251.
Papp K, Bissonnette R, Rosoph L, Wasel N, Lynde CW, Searles G, et al. Efficacy of ISA247 in plaque psoriasis: a randomized multicentre, double-blind, placebo-controlled phase III study. Lancet. 2008;371:1337-1342.
Stern RS. Psoralen and ultraviolet A light therapy for psoriasis. N Engl J Med. 2007;357:682-690.
U.S. Food and Drug Administration. CDER Drug and Biologic Approvals for Calendar Year 2006 -- Updated through August 31, 2006. Last accessed on 15 October, 2006.
Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. BMJ. 2007;334:1218-1220.